Leerink Partners Reiterates Outperform on Aquestive Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has reiterated its Outperform rating on Aquestive Therapeutics and raised the price target from $10 to $12.
September 30, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leerink Partners has reiterated its Outperform rating on Aquestive Therapeutics and increased the price target from $10 to $12, indicating a positive outlook.
The reiteration of an Outperform rating and an increased price target from a reputable analyst firm like Leerink Partners suggests a positive sentiment towards Aquestive Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100